Delivery Order SPE2DB20D1109-SPE2DB25FP59G
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,544.36 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension in 60 mL quantities. This firm fixed-price delivery order was competitively awarded without a set-aside designation and is scheduled for completion by August 11, 2025. The product will be sourced from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $1,918.40 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities. This is a non-set-aside contract with performance scheduled for completion by August 5, 2025, with the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order represents a child contract executed under...
- The Defense Logistics Agency awarded a $1,314.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (60ml), with an ultimate completion date of August 1, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,283.02 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (180 ml), with a completion date of July 31, 2025. This non-set-aside, competitively awarded contract employs firm fixed-price pricing and represents a child order under AmerisourceBergen's broader pharmaceutical supply agreements. The product will be delivered to the company's headquarters in Conshohocken, Pennsylvania. This delivery order falls...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $3,527.50 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension (120 mL) on August 5, 2025, with completion targeted for August 6, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under a larger indefinite delivery contract vehicle. The product will be performed at AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities, valued at $1,182.78. This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a non-competitive set-aside award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract is issued as a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity, valued at $1,082.52 under a firm fixed-price contract. This delivery order was competitively awarded without set-aside designation and is scheduled for completion by July 31, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for...
- The Defense Logistics Agency awarded a $2,566.79 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (180 mL), with an ultimate completion date of August 4, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical product will be performed and...
- The Defense Logistics Agency awarded a delivery order valued at $3,154.08 to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities. This non-set-aside, firm fixed-price delivery order is scheduled for completion by August 6, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement action typical of DLA's ongoing medical...
- The Defense Logistics Agency awarded a delivery order valued at $6,031.38 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension (120 mL) on August 13, 2025, with an ultimate completion date of August 14, 2025. This contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. The pharmaceutical product will be delivered to the vendor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP59GDelivery Order
The Defense Logistics Agency awarded a $2,628.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml). This contract is non-set-aside and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, has been competitively awarded this delivery order as part of its comprehensive pharmaceutical supply relationship with DLA. The broader IDC vehicle under which this award falls provides critical medical support to military healthcare systems, the Defense Health Agency, U.S. Coast Guard, and other federal healthcare programs worldwide. The company's extensive portfolio of federal medical supply contracts demonstrates its capability to fulfill diverse pharmaceutical requirements across multiple therapeutic domains through the DLA Medical Supply Chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.6k | 8/18/25 |